http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : 황인경(Ingyoung Hwang) (검색결과 1 건)
- 무료
- 기관 내 무료
- 유료
-
신약의 적응증 확대와 가치평가 방안 연구 : 면역항암제와 표적항암제를 중심으로
하소영(So-Young Ha),강동원(Dong-Won Kang),황인경(Ingyoung Hwang),박미혜(Mi-Hai Park) 대한약학회 2021 약학회지 Vol.65 No.2
Anticancer drugs with multi-indications have recently increased, which creates the need for a new pricing system that reflects the value of each indication. This study aims to describe the current status of the expansion of reimbursement coverage of anticancer drugs in Korea. Immunotherapy and targeted therapy were analyzed to find out the status of approval and listing. We identified the status of the expansion of reimbursement coverage and the price reduction rate. A survey was conducted with pharmaceutical employees to find their opinions on the current and newly suggested pricing system. In South Korea, 54 anticancer drugs (four immunotherapy and 50 targeted therapy drugs) had been reimbursed by April 2020. Three out of the four immunotherapy drugs (75.0%) and 29 of the 50 targeted therapy drugs (58.0%) were confirmed to have multi-indications. Among them, all four immunotherapy drugs and 25 (86.2%) of the targeted therapy drugs had their reimbursement coverage expanded. The price reduction also stood out as the expansion of the reimbursement coverage increased. Most pharmaceutical employees had recognized a problem with the current drug pricing system and were aware of the need to improve it. Therefore, the drug pricing system needs to be changed to one that reflects the value of the drug when the indication is expanded.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
